Injections: Clinical Trials

506 trials of Injections, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

179 completed, 131 recruiting, 72 unknown, 39 not yet recruiting. 506 Phase 1, 177 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1506Completed 179, Recruiting 131, Unknown 72, Not yet recruiting 39, Terminated 33, Active not recruiting 27, Withdrawn 16, Suspended 6, Enrolling by invitation 3
Phase 2177Recruiting 64, Completed 39, Unknown 24, Not yet recruiting 18, Terminated 12, Active not recruiting 11, Withdrawn 6, Enrolling by invitation 2, Suspended 1

Follow Injections: new trials by email Literature Review of Injections trials Research Report on Injections

Trials (filtered) newest first · largest first

All 506 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of T320, an Anti-Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors
T320 for Injection - Advanced Solid Tumor (Phase 1)
Phase 1Not yet recruitingNanolattix Biotechnology Co., Ltd.1502027-12-012026-02-25
A Clinical Study of MHB034C for Injection in Participants With Advanced Solid Tumors
MHB034C for Injection - Advanced Malignant Solid Tumor
Phase 1 / Phase 2Not yet recruitingMinghui Pharmaceutical (Shanghai) LTD4002026-12-202026-11-10
Immunotherapy and Irreversible Electroporation (IRE) in the Treatment of Locally Advanced Pancreatic Adenocarcinoma
1.0% IP-001 for injection, Irreversible Electroporation - Locally Advanced Pancreatic Adenocarcinoma
Phase 1Not yet recruitingRobert C. Martin102026-12-012026-11-12
Clinical Trial of GenSci136 in Patients With Myasthenia Gravis
GenSci136 for injection - Patients With MG (gMG and oMG)
Phase 1 / Phase 2Not yet recruitingChangchun GeneScience Pharmaceutical Co., Ltd.722026-12-012026-11-13
A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC
HS-20093 for Injection, ZG006, Adebrelimab Injection - Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase 1Not yet recruitingHansoh BioMedical R&D Company3382026-11-152026-10-23
A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234
AZD9550 solution for injection, AZD6234 solution for injection, Formulation 1 solution for injection - Healthy Participants
Phase 1Not yet recruitingAstraZeneca602026-11-092026-11-02
Brain Dopamine Dynamics in Obesity
Milkshake, NeuroEXPLORER, [11C]raclopride - Obesity
Phase 1Not yet recruitingYale University1002026-11-012026-11-04
A Study of MBS314 for Injection in Participants With Relapsed/Refractory Multiple Myeloma.
MBS314 for Injection - Multiple Myeloma
Phase 1 / Phase 2Not yet recruitingBeijing Mabworks Biotech Co., Ltd.782026-11-012026-11-04
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX49 in Advanced/Metastatic Solid Tumors
HLX49, Trastuzumab Deruxtecan for Injection (T-DXd) - Advanced/Metastatic Solid Tumors
Phase 1Not yet recruitingShanghai Henlius Biotech2222026-11-012026-11-18
A First-in-human Trial of SZN-8141 in Diabetic Macular Edema
SZN-8141 for Injection - Diabetic Macular Edema (DME)
Phase 1Not yet recruitingSurrozen Operating, Inc.92026-10-302026-09-14
A Study of RT036 in Patients With Advanced Solid Tumors
RT036 for injection - Advanced Malignant Solid Tumours
Phase 1 / Phase 2Not yet recruitingShanghai Ruotuo Biosciences Co., Ltd.3082026-10-302026-09-28
A Clinical Study of SHR-4595 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability and Pharmacokinetics
SHR-4595 for Injection - Solid Tumor
Phase 1RecruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.2082026-10-202026-11-02
A Phase I/II of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors
LM-364 for injection, Tislelizumab - Advanced Solid Tumor Cancer
Phase 1 / Phase 2Enrolling by invitationLaNova Medicines Limited902026-10-202026-11-10
A Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of SFL-0821 in Adults With FSHD
SFL-0821 for injection, Placebo - Facioscapulohumeral Muscular Dystrophy (FSHD)
Phase 1 / Phase 2RecruitingSoufflé Therapeutics, Inc.902026-10-142026-11-17
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
modified FOLFIRINOX, Pentamidine 300 MG Injection - Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 1RecruitingUniversity of Oklahoma302026-10-062026-11-06
A Study of AK157D1 for Injection in Advanced Solid Tumors
AK157D1 for injection - Advanced Solid Tumors
Phase 1RecruitingAkeso2432026-09-302026-10-13
A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma
LBL-024 for Injection, Bevacizumab injection, Oxaliplatin injection - Metastatic Colorectal Carcinoma
Phase 1 / Phase 2RecruitingNanjing Leads Biolabs Co.,Ltd3692026-09-282026-10-16
A Trial to Evaluate the Safety, Immunogenicity and the Optimal Dose of MOPEVAC-Las Vaccine Candidate Against Lassa Fever
Low dose MOPEVAC-Las vaccine, Intermediate dose MOPEVAC-Las vaccine, High dose MOPEVAC-Las vaccine - Lassa Fever
Phase 1RecruitingInstitut Pasteur722026-09-282026-10-13
Phase 1/2 Clinical Study of HY07121 for Injection (Subcutaneous) in Patients With Advanced Solid Tumors
Test Product HY07121 for Injection (Subcutaneous) - Safety, Tolerability
Phase 1 / Phase 2Not yet recruitingSichuan Huiyu Pharmaceutical Co., Ltd2542026-09-082026-08-27
A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)+Bevacizumab injection, TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets) - Colorectal Cancer
Phase 1 / Phase 2RecruitingChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.712026-09-032026-09-22

Showing 20 of 506. Sign in to see all of them.

Conditions studied

Leukemia, Myeloid, Acute (35)  ·  Breast Neoplasms (18)  ·  Myelodysplastic Syndromes (16)  ·  Neoplasms (16)  ·  Carcinoma, Non-Small-Cell Lung (14)  ·  Neoplasm Metastasis (12)  ·  Prostatic Neoplasms (12)  ·  Multiple Myeloma (10)  ·  Pancreatic Neoplasms (10)  ·  COVID-19 (9)  ·  Colorectal Neoplasms (9)  ·  Melanoma (9)  ·  Recurrence (9)  ·  Ovarian Neoplasms (7)  ·  Small Cell Lung Carcinoma (7)

Sponsors

Chinese PLA General Hospital (15)  ·  Bio-Thera Solutions (13)  ·  Nanjing Leads Biolabs Co.,Ltd (11)  ·  RemeGen Co., Ltd. (10)  ·  Suzhou Suncadia Biopharmaceuticals Co., Ltd. (10)  ·  CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (9)  ·  Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (9)  ·  M.D. Anderson Cancer Center (9)  ·  Suzhou Zelgen Biopharmaceuticals Co.,Ltd (9)  ·  Ascentage Pharma Group Inc. (7)  ·  Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (7)  ·  GE Healthcare (6)  ·  Minghui Pharmaceutical (Hangzhou) Ltd (6)  ·  National Cancer Institute (NCI) (6)  ·  Changchun GeneScience Pharmaceutical Co., Ltd. (5)

Countries

China (258)  ·  United States (138)  ·  Australia (20)  ·  Canada (12)  ·  Germany (10)  ·  United Kingdom (10)  ·  South Korea (7)  ·  Egypt (5)  ·  France (5)  ·  Russia (5)  ·  Spain (5)  ·  Japan (3)  ·  New Zealand (3)  ·  Brazil (2)  ·  Finland (2)

Top investigators

Jason Wu (8)  ·  Weidong Han, Ph.D (6)  ·  Charles Cunningham, PhD (3)  ·  Yifan Zhai, M.D., Ph.D. (3)  ·  Yifan Zhai, MD, PhD (3)  ·  Yuankai Shi, MD (3)  ·  Elizabeth Griffiths (2)  ·  Fang Pei, PhD-c (2)  ·  Francois Lebel, MD (2)  ·  Gangxiong Huang, MD (2)  ·  Gina Keiffer, MD (2)  ·  Giovanni DeCastro (2)  ·  Guido Marcucci (2)

Results publications

PMID 33051668, PMID 33208914, PMID 36796484, PMID 12750546, PMID 15570202, PMID 17342504, PMID 19439093, PMID 21784508, PMID 22214491, PMID 22513884, PMID 22546715, PMID 23374478, PMID 23642437, PMID 24193798, PMID 24565698, PMID 24989138, PMID 25213161, PMID 25387217, PMID 25981818, PMID 26182965, PMID 26755520, PMID 27635086, PMID 27731549, PMID 28039265, PMID 29136037, PMID 29567781, PMID 30213452, PMID 30522017, PMID 30642373, PMID 31262767, PMID 31288365, PMID 31434361, PMID 31496628, PMID 31535238, PMID 31575415, PMID 31601801, PMID 31680180, PMID 31699083, PMID 32077361, PMID 32087818, PMID 32401633, PMID 32615331, PMID 32877576, PMID 33062947, PMID 33139139, PMID 33148815, PMID 33446655, PMID 33787584, PMID 33846844, PMID 34339267

NIH funding

P30CA033572 (5), 2023 (3), 2019 (2), P30CA015704 (2), P30CA016056 (2), P30CA016058 (2), U01CA076576 (2), U10CA180886 (2), UM1CA186712 (2), 2018 (1), 5UM1AI148684-03 (1), K23HL159292 (1), P30CA015083 (1), P30CA072720 (1), P50CA159981 (1)